Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well binimetinib and nivolumab work in treating patients with
BRAF V600 wildtype melanoma that has spread to nearby tissues or lymph nodes and cannot be
removed by surgery (locally advanced unresectable) or has spread to other places in the body
(metastatic). Binimetinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help
the body's immune system attack the cancer, and may interfere with the ability of tumor cells
to grow and spread. Giving binimetinib and nivolumab together may work better in treating
patients with melanoma compared to nivolumab alone.
Phase:
Phase 2
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborators:
Array BioPharma Bristol-Myers Squibb National Cancer Institute (NCI)